Cargando…

Long-term treatment outcomes of temozolomide-based chemoradiation in patients with adult-type diffuse IDH-mutant grade 2 astrocytoma

PURPOSE: To report the long-term outcomes in adult patients with grade 2 IDH-mutant astrocytoma treated with temozolomide (TMZ)-based chemoradiation. Methods: One hundred and three patients with histologically proven grade 2 astrocytoma received radiation therapy (RT), 50.4–54 Gy in 1.8 Gy fractions...

Descripción completa

Detalles Bibliográficos
Autores principales:	Minniti, Giuseppe, Paolini, Sergio, Antonelli, Manila, Gianno, Francesca, Tini, Paolo, Lanzetta, Gaetano, Arcella, Antonella, De Pietro, Raffaella, Giraffa, Martina, Capone, Luca, Romano, Andrea, Bozzao, Alessandro, Esposito, Vincenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522719/ https://www.ncbi.nlm.nih.gov/pubmed/37665475 http://dx.doi.org/10.1007/s11060-023-04418-z

Ejemplares similares

Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3
por: Weller, Jonathan, et al.
Publicado: (2022)

Leptomeningeal disease and brain control after postoperative stereotactic radiosurgery with or without immunotherapy for resected brain metastases
por: Minniti, Giuseppe, et al.
Publicado: (2021)

Pattern of Recurrence of Glioblastoma Versus Grade 4 IDH-Mutant Astrocytoma Following Chemoradiation: A Retrospective Matched-Cohort Analysis
por: Stewart, James, et al.
Publicado: (2022)

Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis
por: Lee, Kwanghoon, et al.
Publicado: (2023)

Single-isocenter multiple-target stereotactic radiosurgery for multiple brain metastases: dosimetric evaluation of two automated treatment planning systems
por: Raza, Giorgio Hamid, et al.
Publicado: (2022)

Deep Learning Can Differentiate IDH-Mutant from IDH-Wild GBM
por: Pasquini, Luca, et al.
Publicado: (2021)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma
por: Sabunga, Olivia Desty, et al.
Publicado: (2022)

Global DNA methylation profiling reveals chromosomal instability in IDH-mutant astrocytomas
por: Liu, Yan, et al.
Publicado: (2022)

LGG-45. A REPORT OF IDH-MUTANT BRAINSTEM ASTROCYTOMAS IN YOUNG ADULTS
por: Chang, Ellen, et al.
Publicado: (2020)

Grading of IDH-mutant astrocytoma using diffusion, susceptibility and perfusion-weighted imaging
por: Yang, Xiefeng, et al.
Publicado: (2022)

Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting
por: Rautajoki, Kirsi J., et al.
Publicado: (2023)

Radiation therapy for atypical and anaplastic meningiomas: an overview of current results and controversial issues
por: Vagnoni, Lorenzo, et al.
Publicado: (2022)

IDH-mutant astrocytoma with EGFR amplification—Genomic profiling in four cases and review of literature
por: Umphlett, Melissa, et al.
Publicado: (2022)

Protocol to establish a genetically engineered mouse model of IDH1-mutant astrocytoma
por: Shi, Diana D., et al.
Publicado: (2023)

PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas
por: Koncar, Robert F., et al.
Publicado: (2017)

From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas
por: Sun, Xueyuan, et al.
Publicado: (2021)

Immuno-phenotyping of IDH-mutant grade 3 astrocytoma and IDH-wildtype glioblastoma reveals specific differences in cells of myeloid origin
por: Raghavan, Jayashree V., et al.
Publicado: (2021)

Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis
por: Minniti, Giuseppe, et al.
Publicado: (2011)

PATH-14. GENETIC SUSCEPTIBILITY AND OUTCOMES OF PEDIATRIC, ADOLESCENT AND YOUNG ADULT IDH-MUTANT ASTROCYTOMAS
por: Bornhorst, Miriam, et al.
Publicado: (2020)

Cystathionine-γ-lyase drives antioxidant defense in cysteine-restricted IDH1-mutant astrocytomas
por: Cano-Galiano, Andrés, et al.
Publicado: (2021)

NI-1 METHYLTHIOADENOSINE PHOSPHOLYLASE STATUS CORRELATES WITH PROGNOSIS AND METHIONINE UPTAKE IN IDH MUTANT ASTROCYTOMA
por: Yamamura, Toshihiro, et al.
Publicado: (2022)

Metabolic biomarkers of radiotherapy response in plasma and tissue of an IDH1 mutant astrocytoma mouse model
por: Ruiz-Rodado, Victor, et al.
Publicado: (2022)

MRI-Based Radiomics Combined with Deep Learning for Distinguishing IDH-Mutant WHO Grade 4 Astrocytomas from IDH-Wild-Type Glioblastomas
por: Hosseini, Seyyed Ali, et al.
Publicado: (2023)

NI-6 Preoperative differential diagnosis of grade II and grade III in cases with astrocytoma, IDH mutant
por: Yano, Hirohito, et al.
Publicado: (2021)

IDH-mutant Astrocytoma Arising in the Brainstem with Symptom Improvement by Foramen Magnum Decompression: A Case Report
por: NAGASE, Takayuki, et al.
Publicado: (2023)

MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas
por: ABE, Hideaki, et al.
Publicado: (2018)

Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis
por: Suwala, Abigail K., et al.
Publicado: (2020)

FSMP-07. CYSTATHIONINE-Γ-LYASE DRIVES ANTIOXIDANT DEFENSE IN CYSTEINE-RESTRICTED IDH1 MUTANT ASTROCYTOMAS
por: Cano-Galiano, Andrés, et al.
Publicado: (2021)

MPC-10 Prognostic analysis in IDH mutant astrocytoma patient with CDKN2A/B homozygous deletion
por: Yanagisawa, Shunsuke, et al.
Publicado: (2021)

Impact of Inversion Time for FLAIR Acquisition on the T2-FLAIR Mismatch Detectability for IDH-Mutant, Non-CODEL Astrocytomas
por: Kinoshita, Manabu, et al.
Publicado: (2021)

Molecular landscape of IDH-mutant astrocytoma and oligodendroglioma grade 2 indicate tumor purity as an underlying genomic factor
por: Zhao, Binghao, et al.
Publicado: (2022)

CDKN2A/B mutations and allele-specific alterations stratify survival outcomes in IDH-mutant astrocytomas
por: Hickman, Richard A., et al.
Publicado: (2023)

Genetic alterations that deregulate RB and PDGFRA signaling pathways drive tumor progression in IDH2-mutant astrocytoma
por: Tateishi, Kensuke, et al.
Publicado: (2023)

Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas
por: Omar, Ayman I, et al.
Publicado: (2010)

Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma
por: Lin, Lin, et al.
Publicado: (2021)

Integrated DNA methylation analysis identifies topographical and tumoral biomarkers in pilocytic astrocytomas
por: Antonelli, Manila, et al.
Publicado: (2018)

Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience
por: Cho, Uiju, et al.
Publicado: (2021)

Current status and perspectives of interventional clinical trials for brain metastases: analysis of ClinicalTrials.gov
por: Tini, Paolo, et al.
Publicado: (2023)

Rare Cases of IDH1 Mutations in Spinal Cord Astrocytomas
por: Konovalov, N. A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_91glptjdiicfuu4tl3bdadmtqq